FOLH1 and prostate cancer: Still, future multicenter external validation is needed to demonstrate true benefits of PSMA radiomics over standard PET metrics in these small prostate cancer lesions, especially since using different PET systems with potentially different imaging protocols might negatively affect radiomics-based predictions more than those based on standard PET features.